PHARMAC statement on Herceptin 12 month funding

PHARMAC statement on Herceptin 12 month funding

PHARMAC has played its part in the decision to fund 12 months Herceptin and will continue to assist the government as required.

PHARMAC’s role has included providing information as necessary, and assisting the Ministry of Health with its contract negotiations with Roche, the supplier of Herceptin.

PHARMAC fully respects the democratic process that has led to the Government’s decision to fund 12 month treatment with Herceptin.

The nine-week treatment course will continue to be fully funded through the Pharmaceutical Schedule.

ENDS

© Scoop Media